The agreed arrangements enable pharmacies to claim a rebate on eligible Vyvanse® stock held on hand prior to the price reduction, with claims processed via pharmacies’ preferred CSO-accredited wholesaler. This approach recognises both the role of wholesalers in the medicines supply chain and the importance of continuity of care for patients.
Anthony Tassone, Chair of the Health Economics and Policy Committee of PGA, said the outcome reflects constructive engagement focused on fairness, patient access and supply-chain sustainability.
These arrangements ensure pharmacies are not left financially worse off as a result of the December 1 price reduction, while reinforcing the critical role that CSO-accredited wholesalers play in supporting timely and efficient supply across Australia.
Anthony Tassone, Chair of the Health Economics and Policy Committee of PGA
“The Guild appreciates Takeda’s willingness to engage constructively and to recognise the real-world impact that PBS price reductions can have on pharmacies, particularly where stock has been held in good faith to support patients during ongoing ADHD medicine shortages,” Mr Tassone said.
“These arrangements ensure pharmacies are not left financially worse off as a result of the December 1 price reduction, while reinforcing the critical role that CSO-accredited wholesalers play in supporting timely and efficient supply across Australia.”
Takeda General Manager for Australia and New Zealand Dave Peace said the company was committed to working collaboratively with the community pharmacy sector to support access to medicines while recognising the operational realities faced by pharmacies.
“Takeda values the critical role community pharmacists play in patient care. We recognise concerns raised following the December 1 list price change for Vyvanse® (lisdexamfetamine dimesilate) and are committed to ensuring pharmacies are not out of pocket,” Mr Pearce said.
Both organisations acknowledged the role of CSO-accredited wholesalers in facilitating the rebate arrangements and supporting pharmacies to submit and process claims efficiently.
Pharmacies have been informed that they need to contact their preferred wholesaler by December 31 2025 to inform them of their stock on hand for Vyvanse® products as of November 30 2025 in order to process the claim.
PGA reiterated its commitment to ongoing advocacy for improved notice periods and better supply-chain impact assessment for future PBS pricing changes and welcomed continued collaboration with manufacturers and wholesalers to support patient access and pharmacy sustainability.
